ACC 2024 | DEDICATE Trial: Transcatheter or Surgical Treatment of Aortic Valve Stenosis

In recent years, TAVR has been increasingly used; however, when it comes to younger, lower risk patients, its use is still challenged.  In this context, there is limited information and we lack randomized studies on “real world” cohorts.  The DEDICATE randomized 1.414 patients over 65 with severe symptomatic aortic stenosis. 701 of these patients received<a href="https://solaci.org/en/2024/04/11/acc-2024-dedicate-trial-transcatheter-or-surgical-treatment-of-aortic-valve-stenosis/" title="Read more" >...</a>

Subutilización del tratamiento médico en enfermedad vascular periférica

ISCHEMIA Outcomes: Does Sex Have Any Impact?

We are well aware of CAD physiopathological disparities and how it manifests differently in men and women. The ISCHEMIA study (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) has revealed that during 3.2 years no differences were seen in the incidence of ischemic events when comparing an invasive strategy (INV) vs a<a href="https://solaci.org/en/2024/03/20/ischemia-outcomes-does-sex-have-any-impact/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

TENDER Study, Evolution at One Year

The use of transcatheter mitral valve intervention for the treatment of mitral valve regurgitation (MR) continues to evolve; at present guidelines only recommend it for inoperable or high surgical risk patients.    So far, many devices have been assessed, some of which have shown promising results, but only for poor surgical candidates.  Researchers looked into the<a href="https://solaci.org/en/2024/03/15/tender-study-evolution-at-one-year/" title="Read more" >...</a>

La cirugía parece superior a la angioplastia en pacientes jóvenes

Sub-Analysis of the REVIVED-BCIS2: Myocardial Viability Changes Prognosis in Ischemic Cardiomyopathy Revascularization?

The purpose of myocardial viability testing is to identify patients that might benefit from revascularization by diagnosing three types of myocardium: normal, viable or hibernating, and scarred (non-viable). Non-randomized studies have shown recovery of a viable ventricle after myocardial revascularization surgery (CABG) and improved survival.  However, a sub-analysis of the main study on viability testing,<a href="https://solaci.org/en/2024/02/10/sub-analysis-of-the-revived-bcis2-myocardial-viability-changes-prognosis-in-ischemic-cardiomyopathy-revascularization/" title="Read more" >...</a>

Disnea y oclusiones totales crónicas: un síntoma que podemos aliviar (o al menos intentarlo)

Contemporary Outcomes of CTO PCI in Europe: The ERCTO Registry

Roughly 20% or coronary angiographies show some form of chronic total occlusion (CTO), and this figure is twice as high for diabetic patients or those with cardiac failure and reduced ejection fraction (EF). CTO percutaneous intervention (PCI) has experienced a significant growth thanks to the development of new techniques and dedicated material. However, a considerable<a href="https://solaci.org/en/2024/02/08/contemporary-outcomes-of-cto-pci-in-europe-the-ercto-registry/" title="Read more" >...</a>

Events According to Revascularization Modality in the ISCHEMIA Trial

The main studies carried out on patients with chronic coronary syndromes (CCS), such as the MASS II, COURAGE, BARI 2D and FAME-2, failed to show benefits in terms of mortality with the invasive approach.  The ISCHEMIA, a large randomized study including patients with moderate to severe ischemia, with without left main disease and with acceptable<a href="https://solaci.org/en/2024/01/31/events-according-to-revascularization-modality-in-the-ischemia-trial/" title="Read more" >...</a>

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Health Status Scores after Transcatheter Repair in Patients with Tricuspid Regurgitation: TRILUMINATE Analysis

Severe tricuspid regurgitation (TR) has been associated with higher mortality and significant limitations to patient quality of life, with considerable rates of hospitalization for cardiac failure (CF). Transcatheter edge-to-edge repair (TEER) with TriClip has been shown effective to reduce symptoms, with low risk of periprocedural complications.  The aim of this study was to assess functional<a href="https://solaci.org/en/2024/01/17/health-status-scores-after-transcatheter-repair-in-patients-with-tricuspid-regurgitation-triluminate-analysis/" title="Read more" >...</a>

Tricuspid Regurgitation: Natural Progression and Prognosis

The prevalence of tricuspid regurgitation (TR) is significant; its prognosis is well known, and severe TR stages are associated with higher mortality and hospitalization for cardiac failure (CF). Seeing as valve disease tends to evolve over time, in advanced stages, we usually check on patients at specified intervals for early identification of potential hemodynamic complications<a href="https://solaci.org/en/2023/12/19/tricuspid-regurgitation-natural-progression-and-prognosis/" title="Read more" >...</a>

Sistema EVOQUE: reemplazo tricuspídeo transcatéter, resultados al año

EVOQUE: Transcatheter Tricuspid Valve Replacement, One-Year Outcomes

Treating tricuspid regurgitation (TR) has gained increasing importance in interventionism. There is abundant literature on the negative natural evolution of this condition and its unfavorable prognosis, as well as the clinical challenges associated to optimal medical treatment.  Among its percutaneous treatment options, both edge-to-edge repair devices (TEER), as showed in TriValve and TRILUMINATE trials, and<a href="https://solaci.org/en/2023/12/15/evoque-transcatheter-tricuspid-valve-replacement-one-year-outcomes/" title="Read more" >...</a>

New Advances in Mitral Regurgitation Devices with Promising Results

Mitral regurgitation (MR) is a frequent valvulopathy and when the optimal medical treatment at maximum tolerated doses is not enough, surgery is the first course of action. And even though edge-to-edge repair with clips has seen substantial improvement, it is currently reserved for those at high risk of surgery.  However, there is an increasing number<a href="https://solaci.org/en/2023/12/15/new-advances-in-mitral-regurgitation-devices-with-promising-results/" title="Read more" >...</a>